Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera®
Authors:
- 1 July 2004
- journal article
- clinical trial
- Published by Elsevier in Contraception
- Vol. 70 (1) , 11-18
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Body weight and risk of oral contraceptive failure*1Obstetrics & Gynecology, 2002
- Contraceptive efficacy and cycle control with the Ortho Evra™/Evra™ transdermal system: the analysis of pooled dataFertility and Sterility, 2002
- INJECTABLE CONTRACEPTIONObstetrics and Gynecology Clinics of North America, 2000
- Contraceptive Failure Rates: New Estimates from the 1995 National Survey of Family GrowthFamily Planning Perspectives, 1999
- Unintended Pregnancy in the United StatesFamily Planning Perspectives, 1998
- Identification of anovulation and transient luteal function using a urinary pregnanediol-3-glucuronide ratio algorithm.Environmental Health Perspectives, 1996
- Medroxyprogesterone acetate (Depo-Provera) use in adolescents: Uterine bleeding and blood pressure patterns, patient satisfaction, and continuation ratesAdolescent and Pediatric Gynecology, 1995
- Oral Contraceptive Pill Use After an Initial Visit to a Family Planning ClinicFamily Planning Perspectives, 1991
- Contraceptive Failure in the United States: An UpdateStudies in Family Planning, 1990